Review article: fructose in non-alcoholic fatty liver disease

被引:51
|
作者
Yilmaz, Y. [1 ,2 ]
机构
[1] Marmara Univ, Inst Gastroenterol, TR-34840 Istanbul, Turkey
[2] Marmara Univ, Sch Med, Dept Gastroenterol, TR-34840 Istanbul, Turkey
关键词
BROWN ADIPOSE-TISSUE; GLYCATION END-PRODUCTS; INDUCED HEPATIC STEATOSIS; SPRAGUE-DAWLEY RATS; METABOLIC SYNDROME; INSULIN-RESISTANCE; DIETARY FRUCTOSE; LIPID-ACCUMULATION; SOLUBLE RECEPTOR; BLOOD-PRESSURE;
D O I
10.1111/j.1365-2036.2012.05080.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The role of excess fructose intake in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) has recently received increasing attention, but the pathophysiology of this relationship has been only partly elucidated. Aini To provide an overview of the potential role played by fructose in the pathogenesis of NAFLD by focusing on both indirect and direct harmful effects. Methods Experimental and clinical studies which investigated the relation of fructose with NAFLD are reviewed. Results Several factors may potentially contribute to fructose-induced NAFLD, including the induction of the metabolic syndrome, copper deficiency, bacterial translocation from the gut to the liver, the formation of advanced glycation endproducts and a direct dysmetabolic effect on liver enzymes. Conclusions Experimentally-increased fructose intake recapitulates many of the pathophysiological characteristics of the metabolic syndrome in humans, which may in turn lead to NAFLD. However, the majority of experimental studies tend to involve feeding excessively high levels of fructose (60-70% of total energy intake) which is not reflective of average human intake. Hopefully, the combination of in vivo, in vitro and genetic research will provide substantial mechanistic evidence into the role of fructose in NAFLD development and its complications.
引用
收藏
页码:1135 / 1144
页数:10
相关论文
共 50 条
  • [1] Review article: new treatments in non-alcoholic fatty liver disease
    Townsend, S. A.
    Newsome, P. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (05) : 494 - 507
  • [2] Review article: the metabolic syndrome and non-alcoholic fatty liver disease
    Loria, P
    Lonardot, A
    Carulli, L
    Verrone, AM
    Ricchi, M
    Lombardini, S
    Rudilosso, A
    Ballestri, S
    Carulli, N
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 : 31 - 36
  • [3] Review article: drug therapy for non-alcoholic fatty liver disease
    Comar, KM
    Sterling, RK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (02) : 207 - 215
  • [4] Review article: diagnosis and treatment of non-alcoholic fatty liver disease
    Oh, M. K.
    Winn, J.
    Poordad, F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (05) : 503 - 522
  • [5] Fructose intake in patients with non-alcoholic fatty liver disease
    Li, Xiao Ying
    Goh, George Boon-Bee
    Shim, Hang Hock
    Fook-Chong, Stephanie Man Chung
    Loh, Yet Hua
    Chow, Wan Cheng
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2019, 28 (04) : 218 - 223
  • [6] Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
    ter Horst, Kasper W.
    Serlie, Mireille J.
    NUTRIENTS, 2017, 9 (09): : 1 - 20
  • [7] The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
    Yu, Siyu
    Li, Chunlin
    Ji, Guang
    Zhang, Li
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [9] Relationship between Diet and Non-alcoholic Fatty Liver Disease: A Review Article
    Mirmiran, Parvin
    Amirhamidi, Zeynab
    Ejtahed, Hanieh-Sadat
    Bahadoran, Zahra
    Azizi, Fereidoun
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2017, 46 (08) : 1007 - 1017
  • [10] Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review
    Coronati, Mattia
    Baratta, Francesco
    Pastori, Daniele
    Ferro, Domenico
    Angelico, Francesco
    Del Ben, Maria
    NUTRIENTS, 2022, 14 (06)